Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
8–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
A total body weight \>25 kg (55 lbs).
Symptoms of urinary frequency (average ≥8 daily bathroom visits to urinate) and urgency to urinate, with or without urgency incontinence, for at least 6 months prior to enrolment, OR
Stable neurological disease and urodynamically confirmed detrusor overactivity, who may require intermittent catheterization for management of urinary drainage.
You may not be if
Treatment with an investigational drug within 4 weeks or 5 half-lives, whichever is longer, before first study dose
Ongoing use of potent CYP3A4 inhibitors or inducers or CYP2D6 inhibitors
Ongoing use of another drug for treating overactive bladder
Uncontrolled narrow angle glaucoma, urinary or gastric retention
Clareo Health | Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years
